Judd, LL, Schettler, PJ, Akiskal, HS, Coryell, W, Leon, AC, Maser, JD, et al Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry
2008; 65: 386–94.
Scott, J, Leboyer, M, Hickie, I, Berk, M, Kapczinski, F, Frank, E, et al Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. Br J Psychiatry
2013; 202: 243–5.
Bourne, C, Aydemir, O, Balanza-Martinez, V, Bora, E, Brissos, S, Cavanagh, JT, et al Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand
2013; 128: 149–62.
Kessing, LV. Cognitive impairment in the euthymic phase of affective disorder. Psychol Med
1998; 28: 1027–38.
Rubinsztein, JS, Michael, A, Paykel, ES, Sahakian, BJ. Cognitive impairment in remission in bipolar affective disorder. Psychol Med
2000; 30: 1025–36.
van Gorp, WG, Altshuler, L, Theberge, DC, Wilkins, J, Dixon, W. Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. A preliminary study. Arch Gen Psychiatry
1998; 55: 41–6.
Tham, A, Engelbrektson, K, Mathe, AA, Johnson, L, Olsson, E, Aberg-Wistedt, A. Impaired neuropsychological performance in euthymic patients with recurring mood disorders. J Clin Psychiatry
1997; 58: 26–9.
Naylor, GJ, Dick, DA, Johnston, BB, Hopwood, SE, Dick, EG, Smith, AH, et al Possible explanation for therapeutic action of lithium, and a possible substitute (methylene-blue). Lancet
1981; 2: 1175–6.
Narsapur, SL, Naylor, GJ. Methylene blue. A possible treatment for manic depressive psychosis. J Affect Disord
1983; 5: 155–61.
Thomas, RD, Callender, K. Methylene blue in treatment of bipolar illness. Biol Psychiatry
1985; 20: 120–1.
Naylor, GJ, Smith, AH, Connelly, P. Methylene blue in mania. Biol Psychiatry
1988; 24: 941–2.
Naylor, GJ, Martin, B, Hopwood, SE, Watson, Y. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry
1986; 21: 915–20.
Naylor, GJ, Smith, AH, Trotter, P. Catalysis of the reduction of vanadate by psychotropic drugs. Neuropharmacology
1983; 22: 653–6.
Naylor, GJ, Smith, AH, Connelly, P. A controlled trial of methylene blue in severe depressive illness. Biol Psychiatry
1987; 22: 657–9.
Eroglu, L, Caglayan, B. Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol Res
1997; 36: 381–5.
Wegener, G, Volke, V, Rosenberg, R. Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br J Pharmacol
2000; 130: 575–80.
Rojas, JC, Bruchey, AK, Gonzalez-Lima, F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol
2012; 96: 32–45.
Yatham, LN, Kennedy, SH, Parikh, SV, Schaffer, A, Beaulieu, S, Alda, M, et al Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord
2013; 15: 1–44.
von Wegerer, J, Hesslinger, B, Berger, M, Walden, J. A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Eur Neuropsychopharmacol
1997; 7: 77–81.
Zona, C, Avoli, M. Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia
1997; 38: 522–5.
Wang, SJ, Sihra, TS, Gean, PW. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport
2001; 12: 2255–8.
Hassel, B, Tauboll, E, Gjerstad, L. Chronic lamotrigine treatment increases rat hippocampal GABA shunt activity and elevates cerebral taurine levels. Epilepsy Res
2001; 43: 153–63.
Cunningham, MO, Jones, RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology
2000; 39: 2139–46.
Crumrine, RC, Bergstrand, K, Cooper, AT, Faison, WL, Cooper, BR. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. Stroke
1997; 28: 2230–6.
Ingram, DK, Spangler, EL, Iijima, S, Kuo, H, Bresnahan, EL, Greig, NH, et al New pharmacological strategies for cognitive enhancement using a rat model of age-related memory impairment. Ann NY Acad Sci
1994; 717: 16–32.
Schuman, EM, Meffert, MK, Schulman, H, Madison, DV. An ADP-ribosyltransferase as a potential target for nitric oxide action in hippocampal long-term potentiation. Proc Natl Acad Sci USA
1994; 91: 11958–62.
Park, C, Kang, M, Kwon, YK, Chung, JH, Ahn, H, Huh, Y. Inhibition of neuronal nitric oxide synthase enhances cell proliferation in the dentate gyrus of the adrenalectomized rat. Neurosci Lett
2001; 309: 9–12.
Spitzer, RL, Endicott, J, Robins, E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry
1978; 35: 773–82
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (4th edn) (DSM-IV).
Endicott, J, Spitzer, RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry
1978; 35: 837–44.
Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry
1960; 23: 56–62.
Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry
1978; 133: 429–35.
Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry
1979; 134: 382–9.
Hamilton, M. The assessment of anxiety states by rating. Br J Med Psychol
1959; 32: 50–5.
Spearing, MK, Post, RM, Leverich, GS, Brandt, D, Nolen, W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatr Res
1997; 73: 159–71.
Coppen, A, Montgomery, SA, Gupta, RK, Bailey, JE. A double-blind comparison of lithium carbonate and maprotiline in the prophylaxis of the affective disorders. Br J Psychiatry
1976; 128: 79–85.
Delis, D, Kramer, J, Kaplan, E, Ober, BA. The California Verbal Learning Test.
Psychological Corporation, 1987.
Jacoby, LL. Invariance in automatic influences of memory: toward a user's guide for the process-dissociation procedure. J Exp Psychol Learn Mem Cogn
1998; 24: 3–26.
van Gorp, WG, Altshuler, L, Theberge, DC, Mintz, J. Declarative and procedural memory in bipolar disorder. Biol Psychiatry
1999; 46: 525–31.
Martinez-Aran, A, Vieta, E, Colom, F, Reinares, M, Benabarre, A, Torrent, C, et al Neuropsychological performance in depressed and euthymic bipolar patients. Neuropsychobiology
2002; 46 (suppl 1): 16–21.
MacQueen, GM, Galway, TM, Hay, J, Young, LT, Joffe, RT. Recollection memory deficits in patients with major depressive disorder predicted by past depressions but not current mood state or treatment status. Psychol Med
2002; 32: 251–8.
Reitan, R. The relation of the trail making test to organic brain damage. J Consult Psychol
1955; 19: 393–4.
Tipper, SP. The negative priming effect: inhibitory priming by ignored objects. Q J Exp Psychol A
1985; 37: 571–90.
Posner, MI, Cohen, Y. Components of visual orienting. In Attention and Performance X: Control of Language Processes (eds Bouma, H, Bouwhuis, D): 531–56. Erlbaum, 1984.
MacQueen, GM, Grof, P, Alda, M, Marriott, M, Young, LT, Duffy, A. A pilot study of visual backward masking performance among affected versus unaffected offspring of parents with bipolar disorder. Bipolar Disord
2004; 6: 374–8.
Gillman, PK. CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol
2011; 25: 429–36.
US Food and Drug Administration. FDA Drug Safety Communication: Updated Information about the Drug Interaction Between Methylene Blue (Methylthioninium Chloride) and Serotonergic Psychiatric Medications.
FDA, 2011 (http://www.fda.gov/Drugs/DrugSafety/ucm276119.htm).